The Present and Future of Clinical Management in Metastatic Breast Cancer.

ABSTRACT: Regardless of the advances in our ability to detect early and treat breast cancer, it is still one of the common types of malignancy worldwide, with the majority of patients decease upon metastatic disease. Nevertheless, due to these advances, we have extensively characterized the drivers and molecular profiling of breast cancer and further dividing it into subtypes. These subgroups are based on immunohistological markers (Estrogen Receptor-ER; Progesterone Receptor-PR and Human Epidermal Growth Factor Receptor 2-HER-2) and transcriptomic signatures with distinct therapeutic approaches and regiments. These therapeutic approaches include targeted therapy (HER-2⁺), endocrine therapy (HR⁺) or chemotherapy (TNBC) with optional combination radiotherapy, depending on clinic

SUBMITTER: Lin PH 

PROVIDER: S-EPMC9573678 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature